Literature DB >> 23934479

[Tumor-induced hypercalcemia].

O Hopfer1, A Gawliczek, M G Kiehl.   

Abstract

Hypercalcemia is in many cases a symptom of advanced stage malignant diseases due to increased resorption and reduced secretion. A slightly increased hypercalcemia is mostly asymptomatic but high calcium levels are associated with neurological, gastrointestinal, cardiac and renal symptoms. Important diagnostic tools are the determination of serum albumin and ionized calcium levels. Therapeutic intervention depends on the clinical symptoms as well as calcium levels. Furthermore, increase over time and duration of hypercalcemia has to be taken into account. The principles of treatment are sufficient fluid replacement and maintaining adequate diuresis. In addition, calcitonin, bisphosphonates and steroids are effective and widely used to decrease plasma calcium levels.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23934479     DOI: 10.1007/s00108-013-3262-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  30 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

2.  Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia.

Authors:  S H Ralston; S J Gallacher; U Patel; F J Dryburgh; W D Fraser; R A Cowan; I T Boyle
Journal:  Lancet       Date:  1989-11-18       Impact factor: 79.321

3.  Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: Case reports.

Authors:  Dirk Henrich; Martin Hoffmann; Michael Uppenkamp; Raoul Bergner
Journal:  Acta Haematol       Date:  2006       Impact factor: 2.195

4.  Diagnostic approach to hypercalcemia: relevance of parathyroid hormone and parathyroid hormone-related protein measurements.

Authors:  J -P. Casez; R Pfammatter; Q -V. Nguyen; K Lippuner; P Jaeger
Journal:  Eur J Intern Med       Date:  2001-07       Impact factor: 4.487

5.  Hypercalcemia with excess serum 1,25 dihydroxyvitamin D in lymphomatoid granulomatosis/angiocentric lymphoma.

Authors:  S J Scheinman; M W Kelberman; A H Tatum; K W Zamkoff
Journal:  Am J Med Sci       Date:  1991-03       Impact factor: 2.378

6.  Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia.

Authors:  N Sawyer; C Newstead; A Drummond; J Cunningham
Journal:  Bone Miner       Date:  1990-05

Review 7.  Mechanisms of bone lesions in multiple myeloma and lymphoma.

Authors:  G D Roodman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

8.  Estrogens and antiestrogens stimulate release of bone resorbing activity by cultured human breast cancer cells.

Authors:  A Valentin-Opran; G Eilon; S Saez; G R Mundy
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

9.  Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia.

Authors:  K Nakayama; S Fukumoto; S Takeda; Y Takeuchi; T Ishikawa; M Miura; K Hata; M Hane; Y Tamura; Y Tanaka; M Kitaoka; T Obara; E Ogata; T Matsumoto
Journal:  J Clin Endocrinol Metab       Date:  1996-02       Impact factor: 5.958

10.  Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).

Authors:  P J Ling; R P A'Hern; J R Hardy
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.